- BioIntelliSense has acquired clinical intelligence and triage system AlertWatch to expand the set of technologies distributed in the U.S. through its partnership with Medtronic.
- AlertWatch sells a dashboard that aggregates data to give clinicians an overview of patient vital sign trends. Physicians have used the system in more than one million surgeries and 25,000 births.
- Under the terms of a recent agreement, Medtronic will distribute AlertWatch to hospitals in the U.S. alongside BioIntelliSense’s wearable device for continuous remote monitoring.
AlertWatch provides systems aimed at operating rooms, intensive care units, and labor and delivery units. The systems display and analyze data from inpatient vital signs, electronic medical records, laboratory systems and BioIntelliSense wearables to provide insights to physicians.
The companies did not disclose the terms of the deal.
Partnering with Golden, Colorado-based BioIntelliSense will “greatly expand the reach and adoption of our world-class clinical decision support solution,” Dr. Kevin Tremper, founder and president of Ann Arbor, Michigan-based AlertWatch, said in a statement. “The workflow automation benefits not only help to reduce hospital stays and costs, but also assist clinicians and nurses by alerting them with highly actionable information that prioritizes and personalizes patient care.”
In August, Medtronic landed the exclusive U.S. hospital and 30-day post-acute hospital-to-home distribution rights of BioIntelliSense’s BioButton, a wearable for continuous monitoring. The agreement allowed Medtronic’s remote patient monitoring business to offer the BioButton to U.S. hospitals.
Now, with BioIntelliSense expanding its portfolio, Medtronic will also distribute AlertWatch to hospitals in the U.S. Frank Chan, president of Medtronic’s patient monitoring business said the addition of the new system to the offering “enables workflow efficiency for our customers as they monitor patients in hospital and at home.”
BioIntelliSense and AlertWatch are both interoperable platforms that integrate with third-party systems. After disclosing the takeover, BioIntelliSense said it “remains committed to an ecosystem approach.”